Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Razvan Cristescu

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
The Journal of Experimental Medicine|February 10, 2021
Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing miceFilippo Veglia, Ayumi Hashimoto, Harsh Dweep, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2022
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 StudyKeun-Wook Lee, Eric Van Cutsem, Yung-Jue Bang, et al.
JTO Clinical and Research Reports|February 16, 2023
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLCMarina C Garassino, Shirish Gadgeel, Silvia Novello, et al.
JTO Clinical and Research Reports|October 15, 2025
Corrigendum to "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]Marina C Garassino, Shirish Gadgeel, Silvia Novello, et al.
JCO Precision Oncology|April 26, 2023
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory AnalysisSherene Loi, Roberto Salgado, Peter Schmid, et al.
Cancer Medicine|December 8, 2022
Biomarkers predictive of response to pembrolizumab in head and neck cancerDavid G Pfister, Robert I Haddad, Francis P Worden, et al.
Nature Medicine|July 18, 2018
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancerSeung Tae Kim, Razvan Cristescu, Adam J Bass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2018
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028Patrick A Ott, Yung-Jue Bang, Sarina A Piha-Paul, et al.
Science (New York, N.Y.)|October 13, 2018
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapyRazvan Cristescu, Robin Mogg, Mark Ayers, et al.
Gynecologic Oncology|October 20, 2023
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100Jonathan A Ledermann, Ronnie Shapira-Frommer, Alessandro D Santin, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
The Journal of Experimental Medicine|February 10, 2021
Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing miceFilippo Veglia, Ayumi Hashimoto, Harsh Dweep, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2022
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 StudyKeun-Wook Lee, Eric Van Cutsem, Yung-Jue Bang, et al.
JTO Clinical and Research Reports|February 16, 2023
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLCMarina C Garassino, Shirish Gadgeel, Silvia Novello, et al.
JTO Clinical and Research Reports|October 15, 2025
Corrigendum to "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]Marina C Garassino, Shirish Gadgeel, Silvia Novello, et al.
JCO Precision Oncology|April 26, 2023
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory AnalysisSherene Loi, Roberto Salgado, Peter Schmid, et al.
Cancer Medicine|December 8, 2022
Biomarkers predictive of response to pembrolizumab in head and neck cancerDavid G Pfister, Robert I Haddad, Francis P Worden, et al.
Nature Medicine|July 18, 2018
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancerSeung Tae Kim, Razvan Cristescu, Adam J Bass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2018
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028Patrick A Ott, Yung-Jue Bang, Sarina A Piha-Paul, et al.
Science (New York, N.Y.)|October 13, 2018
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapyRazvan Cristescu, Robin Mogg, Mark Ayers, et al.
Gynecologic Oncology|October 20, 2023
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100Jonathan A Ledermann, Ronnie Shapira-Frommer, Alessandro D Santin, et al.
Pageof 6